Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGB3 | P05106 | 14/20 | 1.00 |
| ▸ | ITGB6 | P18564 | 7/20 | 0.72 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.72 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.72 |
| ▸ | ITGB8 | P26012 | 6/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6422137 | 1.00 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB1ITGA2B | |
| SCHEMBL6424064 | 1.00 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB1ITGA2B | |
| SCHEMBL7434333 | 0.90 | ITGAV (0.81) | ITGAVITGB3ITGB6ITGB1ITGA2B | |
| SCHEMBL7440561 | 0.90 | ITGAV (0.81) | ITGAVITGB3ITGB6ITGB1ITGA2B | |
| SCHEMBL7434321 | 0.90 | ITGAV (0.81) | ITGAVITGB3ITGB6ITGB1ITGA2B | |
| SCHEMBL6785411 | 0.89 | ITGAV (0.80) | ITGAVITGB3ITGB6ITGB1ITGA2B | |
| SCHEMBL5246837 | 0.87 | ITGAV (0.77) | ITGAVITGB3ITGB6ITGB1ITGA2B | |
| SCHEMBL5247025 | 0.87 | ITGAV (0.77) | ITGAVITGB3ITGB6ITGB1ITGA2B | |
| SCHEMBL2841311 | 0.86 | ITGB3 (0.79) | ITGAVITGB3ITGB6ITGB1ITGA2B | |
| SCHEMBL5857835 | 0.86 | ITGB3 (0.75) | ITGAVITGB3ITGB6ITGB1ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1040098-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | claimed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | claimed |
| EP-1040098-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-10-04 | — | — | EP | claimed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | claimed |
| WO-1999031061-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | claimed |
| EP-1040098-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-6784190-B2 | USEFUL FOR INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, TUMOR, ATHEROSCLEROSIS, INFLAMMATION, WOUND HEALING, VIRAL DISEASEDISEASE, TUMOR | MERCK & CO., INC. | 2004-08-31 | — | — | US | disclosed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | disclosed |
| US-6297249-B1 | SUBSTITUTED 2-CARBOXYALKYLPYRIDINES | MERCK & CO., INC. | 2001-10-02 | — | — | US | disclosed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010176-A1 | Integrin receptor antagonists | ITGAV, ITGB3, ADGRE5 | ITGAV 1/4885ITGB3 2/4885ITGB6 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.